<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7059311/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Baseline features of the study population</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-."/>
   <th colspan="1" rowspan="1" id="0-1-.">Patients 
    <i>(N = 144)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-2-.">Group A 
    <i>(N = 101)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-3-.">Group B 
    <i>(N = 43)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-4-.">
    <b>
     <i>p-value</i>
    </b>
   </th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>
    <b>Sex, males.</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>71 (49.3%)</td>
   <td>42 (41.6%)</td>
   <td>29 (67.4%)</td>
   <td>
    <b>0.006</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>Age, years, mean (SD)</b>
   </td>
   <td>60 ± 13,5</td>
   <td>64.9 ± 11.7</td>
   <td>50.6 ± 12.1</td>
   <td>
    <b>&lt; 0.001</b>
   </td>
  </tr>
  <tr>
   <td colspan="5">
    <b>Risk Factors</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>IDU</i>
   </td>
   <td>37 (25.7%)</td>
   <td>17 (16.9%)</td>
   <td>20 (46.5%)</td>
   <td>
    <b>&lt; 0.001</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>Heterosexual</i>
   </td>
   <td>10 (7.0%)</td>
   <td>8 (7.9%)</td>
   <td>2 (4.7%)</td>
   <td>0.720</td>
  </tr>
  <tr>
   <td>
    <i>MSM</i>
   </td>
   <td>1 (0.7%)</td>
   <td>0</td>
   <td>1 (2.3%)</td>
   <td>0.290</td>
  </tr>
  <tr>
   <td> Nosocomial</td>
   <td>38 (26.4%)</td>
   <td>31 (30.6%)</td>
   <td>7 (16.3%)</td>
   <td>0.150</td>
  </tr>
  <tr>
   <td>
    <i>Unknown</i>
   </td>
   <td>58 (40.2%)</td>
   <td>45 (44.6%)</td>
   <td>13 (30.2%)</td>
   <td>0.138</td>
  </tr>
  <tr>
   <td colspan="5">
    <b>HCV Genotypes</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>1a</i>
   </td>
   <td>32 (22.2%)</td>
   <td>17 (16.8%)</td>
   <td>15 (34.9%)</td>
   <td>
    <b>0.020</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>1b</i>
   </td>
   <td>51 (35.4%)</td>
   <td>44 (43.6%)</td>
   <td>7 (16.3%)</td>
   <td>
    <b>0.002</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>2</i>
   </td>
   <td>37 (25.7%)</td>
   <td>31 (30.7%)</td>
   <td>6 (13.9%)</td>
   <td>
    <b>0.038</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>3</i>
   </td>
   <td>18 (12.5%)</td>
   <td>5 (4.9%)</td>
   <td>13 (30.2%)</td>
   <td>
    <b>&lt; 0.001</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>4</i>
   </td>
   <td>6 (4.2%)</td>
   <td>4 (4%)</td>
   <td>2 (4.7%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <b>Duration of HCV infection, years (range)</b>
   </td>
   <td>18 (10–25.5)</td>
   <td>20 (11–26)</td>
   <td>17 (9–23)</td>
   <td>0.199</td>
  </tr>
  <tr>
   <td>
    <b>Log 10 HCV-RNA, IU/mL, median (range)</b>
   </td>
   <td>6.00 (5.48–6.52)</td>
   <td>5.9 (5.6–6.5)</td>
   <td>6.2 (5.6–6.6)</td>
   <td>0.095</td>
  </tr>
  <tr>
   <td>
    <b>Liver stiffness, Kpa, mean (SD)</b>
   </td>
   <td>10,8 ± 9,9</td>
   <td>11.5 ± 11.2</td>
   <td>9.1 ± 5.2</td>
   <td>0.518</td>
  </tr>
  <tr>
   <td>
    <b>Previous failure,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>32 (22.2%)</td>
   <td>29 (28.7%)</td>
   <td>3 (7.0%)</td>
   <td>
    <b>0.004</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>INF-based tx</b>
   </td>
   <td>31</td>
   <td>28</td>
   <td>3</td>
   <td/>
  </tr>
  <tr>
   <td>
    <b>DAAs-based tx</b>
   </td>
   <td>1</td>
   <td>1</td>
   <td>0</td>
   <td/>
  </tr>
  <tr>
   <td colspan="5">
    <b>Fibrosis stage,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>F0-F2</i>
   </td>
   <td>78 (54.1%)</td>
   <td>51 (50.5%)</td>
   <td>27 (62.8%)</td>
   <td>0.203</td>
  </tr>
  <tr>
   <td>
    <i>F3</i>
   </td>
   <td>24 (16.7%)</td>
   <td>19 (18.8%)</td>
   <td>5 (11.6%)</td>
   <td>0.338</td>
  </tr>
  <tr>
   <td>
    <i>F4</i>
   </td>
   <td>42 (29.2%)</td>
   <td>31 (30.7%)</td>
   <td>11 (25.6%)</td>
   <td>0.689</td>
  </tr>
  <tr>
   <td>
    <b>FIB-4 score median (range)</b>
   </td>
   <td>2.02 (1.40–3.35)</td>
   <td>2.2 (1.5–3.4)</td>
   <td>1.6 (1.2–2.9)</td>
   <td>
    <b>0.009</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>APRI score median (range)</b>
   </td>
   <td>0.40 (0.60–1.22)</td>
   <td>0.6 (0.4–1.2)</td>
   <td>0.7 (0.4–1.2)</td>
   <td>0.315</td>
  </tr>
  <tr>
   <td>
    <b>MELD score median (range)</b>
   </td>
   <td>7 (6.5–8.5)</td>
   <td>7.0 (6.0–8.0)</td>
   <td>7.0 (6.0–7-0)</td>
   <td>0.923</td>
  </tr>
  <tr>
   <td colspan="5">
    <b>Child-Pugh class</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td> A</td>
   <td>142 (98.6%)</td>
   <td>100 (99.1%)</td>
   <td>42 (97.7%)</td>
   <td>0.510</td>
  </tr>
  <tr>
   <td> B</td>
   <td>2 (1.4%)</td>
   <td>1 (0.99%)</td>
   <td>1 (2.3%)</td>
   <td>0.510</td>
  </tr>
  <tr>
   <td>
    <b>Cirrhosis,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>46 (31.9%)</td>
   <td>34 (33.66%)</td>
   <td>12 (27.9%)</td>
   <td>0.562</td>
  </tr>
  <tr>
   <td>
    <b>Oesophageal varices or portal hypertension,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>15 (10.4%)</td>
   <td>11 (10.89%)</td>
   <td>4 (9.3%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td colspan="5">
    <b>Type of HCV therapy</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td> SOF + RBV</td>
   <td>7 (4.8%)</td>
   <td>6 (5.9%)</td>
   <td>1 (2.3%)</td>
   <td>0.670</td>
  </tr>
  <tr>
   <td> SOF + SMV ± RBV</td>
   <td>5 (3.5%)</td>
   <td>4 (3.9%)</td>
   <td>1 (2.3%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td> SOF + LDV ± RBV</td>
   <td>21 (14.6%)</td>
   <td>15 (14.9%)</td>
   <td>6 (13.9%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td> SOF + DCV ± RBV</td>
   <td>13 (9.0%)</td>
   <td>10 (10%)</td>
   <td>3 (7%)</td>
   <td>0.750</td>
  </tr>
  <tr>
   <td> OMB + PTV/r + DAS ± RBV</td>
   <td>15 (10.4%)</td>
   <td>15 (14.9%)</td>
   <td>0</td>
   <td>
    <b>0.006</b>
   </td>
  </tr>
  <tr>
   <td> OMB + PTV/r + RBV</td>
   <td>2 (1.4%)</td>
   <td>2 (1.9%)</td>
   <td>0</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td> SOF + VEL ± RBV</td>
   <td>37 (25.7%)</td>
   <td>15 (14.9%)</td>
   <td>22 (51.2%)</td>
   <td>
    <b>&lt; 0.001</b>
   </td>
  </tr>
  <tr>
   <td> GLE + PIB</td>
   <td>24 (16.7%)</td>
   <td>17 (16.8%)</td>
   <td>7 (16.3%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td> GRZ + EBR ± RBV</td>
   <td>20 (13.9%)</td>
   <td>17 (16.8%)</td>
   <td>3 (7%)</td>
   <td>0.186</td>
  </tr>
  <tr>
   <td colspan="5">
    <b>Duration of therapy</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>8w</i>
   </td>
   <td>20 (13.9%)</td>
   <td>15 (14.9%)</td>
   <td>5 (11.6%)</td>
   <td>0.794</td>
  </tr>
  <tr>
   <td>
    <i>12w</i>
   </td>
   <td>101 (70.1%)</td>
   <td>67 (66.3%)</td>
   <td>34 (79.1%)</td>
   <td>0.164</td>
  </tr>
  <tr>
   <td>
    <i>16w</i>
   </td>
   <td>6 (4.2%)</td>
   <td>4 (3.9%)</td>
   <td>2 (4.65%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <i>24w</i>
   </td>
   <td>17 (11.8%)</td>
   <td>15 (14.9%)</td>
   <td>2 (4.65%)</td>
   <td>0.097</td>
  </tr>
  <tr>
   <td>
    <b>Addition of RBV</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>33 (22.9%)</td>
   <td>24 (23.74%)</td>
   <td>9 (20.9%)</td>
   <td>0.829</td>
  </tr>
  <tr>
   <td>
    <b>ALT, UI/L, median (range)</b>
   </td>
   <td>50 (30–80)</td>
   <td>47 (26.5–78.5)</td>
   <td>58 (43–93)</td>
   <td>
    <b>0.029</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>Total bilirubin, mg/dL, median (range)</b>
   </td>
   <td>0.62 (0.45–0.85)</td>
   <td>0.65 (0.47–0.82)</td>
   <td>0.60 (0.40–0.87)</td>
   <td>0.323</td>
  </tr>
  <tr>
   <td>
    <b>Serum creatinine, mg/dL, median (range)</b>
   </td>
   <td>0.78 (0.61–0.93)</td>
   <td>0.78 (0.60–0.95)</td>
   <td>0.78 (0.62–0.90)</td>
   <td>0.795</td>
  </tr>
  <tr>
   <td>
    <b>Platelets (×10^9/L), median (range)</b>
   </td>
   <td>183.5 (140.5–217.5)</td>
   <td>184 (145–219)</td>
   <td>182 (137–214)</td>
   <td>0.936</td>
  </tr>
  <tr>
   <td>
    <b>Albumin, mg/dL, median (range)</b>
   </td>
   <td>4.0 (3.7–4.2)</td>
   <td>4.0 (4.7–4.2)</td>
   <td>4.0 (3.8–4.1)</td>
   <td>0.976</td>
  </tr>
  <tr>
   <td>
    <b>Body mass index, median (range)</b>
   </td>
   <td>25.3 (23.3–28.7)</td>
   <td>25.5 (23.8–29.1)</td>
   <td>25.1 (22.4–27.4)</td>
   <td>0.936</td>
  </tr>
  <tr>
   <td>
    <b>Patients with at least 1 other comorbidity, n (%)</b>
   </td>
   <td>101 (70.10%)</td>
   <td>79 (78.2%)</td>
   <td>22 (51.2%)</td>
   <td>
    <b>0.002</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>Diabetes,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>20 (13.9%)</td>
   <td>16 (15.8%)</td>
   <td>4 (9.3%)</td>
   <td>0.431</td>
  </tr>
  <tr>
   <td>
    <b>Hypertension,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>61 (42.4%)</td>
   <td>53 (52.5%)</td>
   <td>8 (18.6%)</td>
   <td>
    <b>&lt; 0.001</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>HBsAg positive,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>2 (1.4%)</td>
   <td>0</td>
   <td>2 (4.7%)</td>
   <td>0.087</td>
  </tr>
  <tr>
   <td>
    <b>HIV infected,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>19 (13.2%)</td>
   <td>9 (8.9%)</td>
   <td>10 (23.3%)</td>
   <td>
    <b>0.030</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>N aviremic pts on ART, n (%)</i>
   </td>
   <td>19 (100%)</td>
   <td>9 (100%)</td>
   <td>10 (100%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <i>CD4</i>
    <sup>
     <i>+</i>
    </sup>
    <i>(cells/μl) median (range)</i>
   </td>
   <td>85 (42–171)</td>
   <td>98 (50–171)</td>
   <td>83.5 (42–186.5)</td>
   <td>0.903</td>
  </tr>
  <tr>
   <td>
    <i>CDC-C Stage n (%)</i>
   </td>
   <td>7 (4.8%)</td>
   <td>4 (3.9%)</td>
   <td>3 (7%)</td>
   <td>0.650</td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <i>Legend</i>: 
   <i>IDU</i> Injecting drug user, 
   <i>MSM</i> Man who have sex with man, 
   <i>INF</i> Interferon, 
   <i>DAA</i> Direct antiviral agent, 
   <i>SOF</i> Sofosbuvir, 
   <i>RBV</i> Ribavirin, 
   <i>SMV</i> Simeprevir, 
   <i>LDV</i> Ledipasvir, 
   <i>DCV</i> Daclatasvir, 
   <i>OMB</i> Ombitasvir, 
   <i>PTV/r</i> Paripatrevir/ritonavir, 
   <i>DSV</i> Dasabuvir, 
   <i>VEL</i> Velpatasvir, 
   <i>GLE</i> Glecaprevir, 
   <i>PIB</i> Pibrentasvir, 
   <i>GRZ</i> Grazoprevir, 
   <i>EBR</i> Elbasvir, 
   <i>ALT</i> Alanine aminotransferase, 
   <i>ART</i> Antiretroviral therapy 
  </p>
 </tfoot>
</table>
